30 closest matches · ranked by relevance
Gender Identity
Primary: Change in Knowledge of TGNC Individuals of Total Number of Locations to Receive Medical Care in Cleveland Known — 3.79 locations
Gender Dysphoria
Primary: Receipt of Gender Affirming Treatment — 769; 687; 292; 468 Participants
HIV Prevention
Primary: PrEP Uptake — 16.2; 11.4 days
Transgender · Depression · Anxiety
Primary: Depression: Score on the Overall Depression Severity & Impairment Scale (ODSIS) — 9.68; 4.82 score on a scale
Transgender Persons · Sexual Health
Primary: Experience of Erotic and Sexual Risk of Transgender Men(Demographic Data, Transgender Affirmation Questionnaire) — 269; 52; 166; 37 Participants
Gender Dysphoria, Adolescent
Primary: Number of Participants Satisfied With Self-Administered DMPA at Initiation — 17 Participants
HIV
Primary: Number of Participants With Viral Suppression (HIV), 6 Months — 31; 33 Participants — p=0.489
Violence, Sexual
Primary: Average Rating on Sexual Assertiveness at Baseline — 2.77 score on a scale
Transgenderism
Primary: Total Testosterone Level in Transgender Female Patients — 498.6; 481.3; 505.3; 62.7 pg/mL — p=0.005
Pelvic Floor Disorders
Primary: Patient Reported Ease of Dilation — 6.6; 7.4; 8.0 units on a scale
HIV · Violence, Gender-Based · Violence, Domestic
Primary: Composite Risk for HIV (CR-HIV) — 0; 1; 9; 1 Participants
Acceptability of Health Care · HIV Infections
Primary: Acceptability Quantitative — 3.5 score on a scale
HIV Prevention · Transgender Health
Primary: Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS) — 973.5; 1078 fmol/punch
Transgender Health · Gender Dysphoria · Transgender Women
Primary: Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) — 17798.14; 18413.21 hr*ng/mL
HIV · Prophylaxis · Transgender
Primary: Change in Maximum Tenofovir Plasma (Cmax) Concentration — 286; 276; 274; 277 ng/mL
HIV
Primary: Change in Percentage of Participants With HIV Transmission Risk at Month 6 — 23.077; 38.462; 46.154; 46.154 percentage of participants with no risk — p=.19
HIV/AIDS · Health Knowledge, Attitudes, Practice · STI
Primary: Self-reported HIV or STI Testing in Past 3 Months — 76; 88 Participants — p=0.914
Uterine Cervical Neoplasms · Sexually Transmitted Diseases
Primary: Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults — 15; 2; 6; 108 Participants…
HIV Infections
Primary: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 — 13; 39 Participants — p=0.0005
HIV
Primary: Change in Condomless Receptive Sex Acts — 1.57; 3.19; 1.43; 1.44 Condomless Receptive Sex Acts
Feasibility Studies
Primary: Acceptability Quantitative — 3.9; 3.8 score on a scale — p=<0.05
HIV
Primary: Number of Participants With HIV Viral Load Suppression in Plasma — 2; 1; 84; 8 Participants
Acceptability of Health Care · HIV Primary Infection
Primary: Acceptability Quantitative — 3.5 score on a scale
Tobacco-Related Carcinoma
Primary: Message Perceived Effectiveness - Persuasive Potential. — 3.57; 3.24; 3.26; 3.44 units on a scale
HIV
Primary: Condomless Intercourse Events — 3.14; 3.17; 3.68 Expected events — p=0.141
HIV Prevention
Primary: Changes in HIV Testing — 102; 100; 87; 83 Participants — p=0.484
Alzheimer Disease · Dementia · Mild Cognitive Impairment
Primary: Change in Physical Activity of Care Recipient — 3.20; 2.76; 3.01; 2.66 days
HIV Infections
Primary: Changes in Intracellular Emtricitabine Triphosphate (FTC-TP) — 0; 3380; 2580; 6470 fmol/1000000 PBMC
Sexual Minority Stress
Primary: Depression — 27.57; 29.70; 26.86; 20.44 score on a scale
Transgender Persons
Primary: Maximum Serum Concentration of Estradiol — 144; 35 pg/mL